SGHT
Sight Sciences, Inc. Health Care Surgical & Medical Instruments & Apparatus Russell 3000
$9.32Close
$498.6MMarket cap
$3.45 – $9.5752-week range
Nov 4, 2026Next report · after the close
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 97 · stronger than 97% of stocks over 12 months
- Near its high 3% below its 52-week high
- Tight base near its pivot pullbacks 19% → 11%; 3.0% above its $9.05 pivot
Cautions
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
3%
1wk
up 3.7%
price change
1mo
down 0.4%
price change
12-month return
up 83%
market up 11% ·
its own up 74%
F-score
5 / 9
Mixed
Altman Z
1.82
Moderate risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
7.8×
price / book
Earnings yield
down 8.3%
EBIT / enterprise value
Cheaper than
14%
of the market · expensive
Revenue growth
down 3%
year on year
EPS growth
—
latest quarter
Sales growth
up 20%
latest quarter · +7 pts
ROE
down 51%
return on equity
Free cash margin
down 39%
-$29.9M FCF
D/E
0.63
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- took on more long-term debt
- issued more shares
- profitability improving
- profits backed by cash
- short-term liquidity improved
- gross margin widened
- assets working harder
Trade setup
ATR%
4.6%
$0.43 a day · 2×ATR $8.45
RS
97 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.0×
vs 50-day average
Up/down volume
1.40
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Contractions
2
19% → 11%
Pivot
$9.05
3.0% above
Volume dry-up
1.0×
10 vs 50 sessions
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 5.0% over the year, from 51m to 53m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 3.1% over the year, from $79.9M to $77.4M.
Last reported
Aug 5, 2026
Results reaction
Aug 5, 2026+26% vs market2 sessions after results
Financials
- Gross 86%
- Net -50%
- Free cash -39%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $27.6M | $49.0M | $71.3M | $81.1M | $79.9M | $77.4M |
| Gross margin | 67% | 82% | 83% | 85% | 85% | 86% |
| Operating income | -$32.2M | -$51.5M | -$84.0M | -$57.3M | -$50.5M | -$37.1M |
| Net income | -$34.7M | -$63.0M | -$86.2M | -$55.5M | -$51.5M | -$38.4M |
| Net margin | -126% | -129% | -121% | -69% | -64% | -50% |
| Earnings per share | — | -$2.36 | -$1.80 | -$1.14 | -$1.03 | -$0.74 |
| Free cash flow | -$33.1M | -$53.4M | -$76.9M | -$48.0M | -$22.7M | -$29.9M |
| Free cash margin | -120% | -109% | -108% | -59% | -28% | -39% |
| Cash | $61.5M | $260.7M | $185.0M | $138.1M | $120.4M | $92.0M |
| Long-term debt | $32.0M | $32.7M | $33.3M | $31.7M | $39.4M | $40.3M |
| Shareholders' equity | -$88.8M | $232.1M | $160.1M | $120.2M | $87.5M | $63.9M |
| Shares outstanding | 9.51m | 47.50m | 48.30m | 49.13m | 50.94m | 53.49m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Mar 4, 2026 | Annual ↗ | Dec 31, 2025 | 63d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Mar 7, 2025 | Annual ↗ | Dec 31, 2024 | 66d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 2, 2024 | Quarterly ↗ | Jun 30, 2024 | 33d |
| May 6, 2024 | Quarterly ↗ | Mar 31, 2024 | 36d |
| Mar 13, 2024 | Annual ↗ | Dec 31, 2023 | 73d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 10, 2026 | Director or officer change ↗ |
| Aug 5, 2026 | Results · Regulation FD ↗ |
| Jun 5, 2026 | Shareholder vote ↗ |
| May 6, 2026 | Results · Regulation FD ↗ |
| Apr 23, 2026 | Regulation FD ↗ |
| Mar 30, 2026 | Regulation FD ↗ |
| Mar 4, 2026 | Results · Regulation FD ↗ |
| Feb 3, 2026 | Material agreement ↗ |
| Jan 13, 2026 | Results ↗ |
| Nov 6, 2025 | Results · Director or officer change · Regulation FD ↗ |
| Oct 17, 2025 | Regulation FD · Other events ↗ |
| Sep 30, 2025 | Material agreement ↗ |